Literature DB >> 20199883

Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome.

Rasmus Sode-Carlsen1, Stense Farholt, Kai Fr Rabben, Jens Bollerslev, Thomas Schreiner, Anne Grethe Jurik, Jens Sandahl Christiansen, Charlotte Höybye.   

Abstract

OBJECTIVE: Prader-Willi syndrome (PWS) is a complex genetic disease associated with hypothalamic-pituitary dysfunction and severe obesity. The aim of the present study was to describe the relationships between body composition, metabolic and hormonal profiles in PWS adults.
METHOD: Forty six adults with genetically verified PWS, 25 women and 21 men, median age 28 years were studied. Body composition was evaluated by standard anthropometric procedures and with computed tomography (CT) of the abdomen and at the mid-femur level. CT of abdomen was compared to 22 healthy, unmatched adults. Circulating lipids were measured and oral glucose tolerance test (OGTT) and hormonal screening including GH secretory capacity (GHRH/arginine test) was carried out.
RESULTS: Median body mass index (BMI) was 27.2 kg/m(2), with women being more obese than men. Sixteen patients had dyslipidaemia, 10 impaired glucose tolerance and seven had diabetes. Fifty percent were hypogonadal and six fulfilled BMI related criteria for growth hormone deficiency (GHD). Visceral to subcutaneous abdominal fat ratio was reduced in PWS. Visceral abdominal fat fraction correlated with both subcutaneous fat, BMI and peak GH-response. Thigh muscle volume was about half of the thigh fat volume. Beneficial effects of sex-steroid replacement on body composition were not observed.
CONCLUSIONS: Body fat was primarily located subcutaneously and metabolic consequences of obesity limited. The abnormal body composition similar to that in non-PWS GHD adults increases the interest of GH treatment in the prevention of obesity in adults with PWS. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20199883     DOI: 10.1016/j.ghir.2009.12.004

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  19 in total

1.  Primary care of adults with developmental disabilities: Canadian consensus guidelines.

Authors:  William F Sullivan; Joseph M Berg; Elspeth Bradley; Tom Cheetham; Richard Denton; John Heng; Brian Hennen; David Joyce; Maureen Kelly; Marika Korossy; Yona Lunsky; Shirley McMillan
Journal:  Can Fam Physician       Date:  2011-05       Impact factor: 3.275

2.  Does segmental body composition differ in women with Prader-Willi syndrome compared to women with essential obesity?

Authors:  G Bedogni; G Grugni; G Tringali; N Marazzi; A Sartorio
Journal:  J Endocrinol Invest       Date:  2015-04-04       Impact factor: 4.256

3.  Effects of growth hormone treatment in adults with Prader-Willi syndrome.

Authors:  M G Butler; B K Smith; J Lee; C Gibson; C Schmoll; W V Moore; J E Donnelly
Journal:  Growth Horm IGF Res       Date:  2013-02-19       Impact factor: 2.372

4.  Visceral adipose tissue area measurement at a single level: can it represent visceral adipose tissue volume?

Authors:  Yusuke Noumura; Tamotsu Kamishima; Kenneth Sutherland; Hideho Nishimura
Journal:  Br J Radiol       Date:  2017-07-14       Impact factor: 3.039

Review 5.  Update on Diabetes Mellitus and Glucose Metabolism Alterations in Prader-Willi Syndrome.

Authors:  Antonino Crinò; Graziano Grugni
Journal:  Curr Diab Rep       Date:  2020-02-06       Impact factor: 4.810

Review 6.  Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.

Authors:  Rasmus Sode-Carlsen; Stense Farholt; Kai Fr Rabben; Jens Bollerslev; Thomas Schreiner; Anne Grethe Jurik; Jens Sandahl Christiansen; Charlotte Höybye
Journal:  Endocrine       Date:  2011-11-12       Impact factor: 3.633

7.  Impaired hypothalamic regulation of endocrine function and delayed counterregulatory response to hypoglycemia in Magel2-null mice.

Authors:  Alysa A Tennese; Rachel Wevrick
Journal:  Endocrinology       Date:  2011-01-19       Impact factor: 4.736

8.  Growth charts for non-growth hormone treated Prader-Willi syndrome.

Authors:  Merlin G Butler; Jaehoon Lee; Ann M Manzardo; June-Anne Gold; Jennifer L Miller; Virginia Kimonis; Daniel J Driscoll
Journal:  Pediatrics       Date:  2014-12-08       Impact factor: 7.124

Review 9.  GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome.

Authors:  Cheri L Deal; Michèle Tony; Charlotte Höybye; David B Allen; Maïthé Tauber; Jens Sandahl Christiansen
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

Review 10.  Growth hormone therapy for Prader-willi syndrome: challenges and solutions.

Authors:  Graziano Grugni; Alessandro Sartorio; Antonino Crinò
Journal:  Ther Clin Risk Manag       Date:  2016-06-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.